(cRGD)2 peptides modified nanoparticles increase tumor-targeting therapeutic effects by co-delivery of albendazole and iodine-131-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

(cRGD)2 peptides modified nanoparticles increase tumor-targeting therapeutic effects by co-delivery of albendazole and iodine-131

Published:2021-07-12 Issue:1 Volume:33 Page:19-29
ISSN:0959-4973
Container-title:Anti-Cancer Drugs
language:en
Short-container-title:

Author:

Liu Shengli,Liu Honglian,Sun Hao,Deng Shengming,Yue Ling,Weng Zhen,Yang Jianfeng,Zuo Bin,He Yang,Zhang Bin

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Pharmacology (medical),Pharmacology,Oncology

Reference35 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.;Bray;CA Cancer J Clin,2018

2. Recent treatment progress of triple negative breast cancer.;Chang-Qing;Prog Biophys Mol Biol,2020

3. Drug delivery and reversal of MDR.;Huang;Mol Pharm,2014

4. Repositioning of anti-parasitic drugs in cyclodextrin inclusion complexes for treatment of triple-negative breast cancer.;Priotti;AAPS Pharmscitech,2018

5. Albendazole as a promising molecule for tumor control.;Castro;Redox Biol,2016

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent Developments in Combination Immunotherapy with Other Therapies and Nanoparticle-Based Therapy for Triple-Negative Breast Cancer (TNBC);Cancers;2024-05-25

2. Albendazole inhibits colon cancer progression and therapy resistance by targeting ubiquitin ligase RNF20;British Journal of Cancer;2024-01-26

3. Current advances in nanoformulations of therapeutic agents targeting tumor microenvironment to overcome drug resistance;Cancer and Metastasis Reviews;2023-07-28

4. Radionuclide 131I-labeled albumin-indocyanine green nanoparticles for synergistic combined radio-photothermal therapy of anaplastic thyroid cancer;Frontiers in Oncology;2022-07-25

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3